India’s vaccine giant invests US $68 million to gain 3.9% stake in UK’s Oxford Biomedica

INDIA – The Serum Institute of India (SII) is set to invest more than US $68.2 million in Oxford Biomedica plc, a biotech group based in the United Kingdom, to fund construction of a facility that will manufacture COVID-19 vaccines. The British biotech firm has announced an investment from world’s largest Coronavirus (COVID-19) vaccine manufacturer by volume. The biotech company anticipates receiving an investment from SII of just over US $68 million, which will be used to fund the development of Oxbox, its 84,000 square foot manufacturing facility in Oxford.…

Read More